MedTrace Logo

Voriconazole as Prophylaxis for Liver Transplant Recipients

NCT00177788 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2012-08-16

No results posted yet for this study

Summary

The study aims to determine if voriconazole prevents invasive fungal infections in liver transplant recipients. Endpoints would be: occurrence of invasive fungal infection and fungal colonization. Two groups will be compared: patients who received voriconazole as prophylaxis and historical controls who did not receive this prophylaxis.

Conditions

  • Fungemia
  • Mycoses

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • David Paterson, MD · University of Pittsburgh Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00177788 on ClinicalTrials.gov